Nitisinone

Inhibitor of 4-Hydroxyphenylpyruvate dioxygenase (HPPD; IC50 = 40 nM1 and 173 nM2) and is in clinical use for the treatment of hereditary tyrosinemia type 13. CD13+ cancer stem cells (CSCs) are dependent on aerobic metabolism of tyrosine - Nitisinone inhibition of tyrosine metabolism results in lowered availability of acetyl-CoA and fumarate for use in the citric acid cycle causing these CSCs to enter cell cycle, decreasing self-renewal, and making them more susceptible to chemotherapy.4 Nitisinone is a potential treatment option for cancers that rely on tyrosine metabolism.